دورية أكاديمية
Long-Term Outcomes following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin
| العنوان: | Long-Term Outcomes following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin |
|---|---|
| المؤلفون: | Kadhim Taqi, Jay Lee, Scott Hurton, Cecily Stockley, Lloyd Mack, Justin Rivard, Walley Temple, Antoine Bouchard-Fortier |
| المصدر: | Current Oncology, Vol 31, Iss 7, Pp 3657-3668 (2024) |
| بيانات النشر: | MDPI AG, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| مصطلحات موضوعية: | colorectal cancer, cytoreductive surgery (CRS), HIPEC, colorectal metastasis, peritoneal carcinomatosis, long-term survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| الوصف: | Background: Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) is a major treatment of colorectal peritoneal carcinomatosis (CPC). The aim was to determine the disease-free survival (DFS) and overall survival (OS) of patients undergoing CRS–HIPEC for CPC and factors associated with long-term survival (LTS). Methods: consecutive CPC patients who underwent CRS–HIPEC at a HIPEC center between 2007 and 2021 were included. Actual survival was calculated, and Cox proportional hazards models were used to identify factors associated with OS, DFS and LTS. Results: there were 125 patients with CPC who underwent primary CRS–HIPEC, with mean age of 54.5 years. Median follow-up was 31 months. Average intraoperative PCI was 11, and complete cytoreduction (CC-0) was achieved in 96.8%. Median OS was 41.6 months (6–196). The 2-year and 5-year OS were 68% and 24.8%, respectively, and the 2-year DFS was 28.8%. Factors associated with worse OS included pre-HIPEC systemic therapy, synchronous extraperitoneal metastasis, and PCI ≥ 20 (p < 0.05). Progression prior to CRS–HIPEC was associated with worse DFS (p < 0.05). Lower PCI, fewer complications, lower recurrence and longer DFS were associated with LTS (p < 0.05). Conclusion: CRS and HIPEC improve OS in CPC patients but they have high disease recurrence. Outcomes depend on preoperative therapy response, extraperitoneal metastasis, and peritoneal disease burden. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1718-7729 1198-0052 |
| Relation: | https://www.mdpi.com/1718-7729/31/7/269; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729 |
| DOI: | 10.3390/curroncol31070269 |
| URL الوصول: | https://doaj.org/article/e523cf9b4de343d1ad1c8b90d4bb39c6 |
| رقم الأكسشن: | edsdoj.523cf9b4de343d1ad1c8b90d4bb39c6 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 17187729 11980052 |
|---|---|
| DOI: | 10.3390/curroncol31070269 |